Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
Go back to Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 28.45 -0.36 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.81 | 52 Week High | $37.39 | |||
| Open | $28.58 | 52 Week Low | $28.25 | |||
| Day High | $28.69 | P/E | 17.24 | |||
| Day Low | $28.38 | EPS | $1.65 | |||
| Volume | 23,791,983 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 2,635,295 | |||||
